Debt-to-equity of Akero Therapeutics, Inc. from 31 Mar 2020 to 30 Sep 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Akero Therapeutics, Inc. quarterly Debt-to-equity in % history and change rate from 31 Mar 2020 to 30 Sep 2025.
  • Akero Therapeutics, Inc. Debt-to-equity for the quarter ending 30 Sep 2025 was 7.3%, a 17% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

Akero Therapeutics, Inc. Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q3 2025 7.3% -1.5% -17% 30 Sep 2025
Q2 2025 8.6% +0.3% +3.6% 30 Jun 2025
Q1 2025 8.7% +0.57% +7% 31 Mar 2025
Q4 2024 9.2% +0.03% +0.33% 31 Dec 2024
Q3 2024 8.8% -0.58% -6.2% 30 Sep 2024
Q2 2024 8.3% -1.4% -15% 30 Jun 2024
Q1 2024 8.2% -4.8% -37% 31 Mar 2024
Q4 2023 9.2% -4% -30% 31 Dec 2023
Q3 2023 9.4% -5.8% -38% 30 Sep 2023
Q2 2023 9.8% -7.1% -42% 30 Jun 2023
Q1 2023 13% +0.35% +2.8% 31 Mar 2023
Q4 2022 13% +3.4% +35% 31 Dec 2022
Q3 2022 15% +7.8% +104% 30 Sep 2022
Q2 2022 17% +11% +196% 30 Jun 2022
Q1 2022 13% +7% +125% 31 Mar 2022
Q4 2021 9.7% +3.6% +59% 31 Dec 2021
Q3 2021 7.5% +0.93% +14% 30 Sep 2021
Q2 2021 5.7% -1.4% -19% 30 Jun 2021
Q1 2021 5.6% +0.28% +5.3% 31 Mar 2021
Q4 2020 6.1% 31 Dec 2020
Q3 2020 6.5% 30 Sep 2020
Q2 2020 7% 30 Jun 2020
Q1 2020 5.3% 31 Mar 2020
* An asterisk sign (*) next to the value indicates that the value is likely invalid.